-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
Velaglucerase alfa in the treatment of Gaucher disease type 1: an update
K Nicole Weaver, Gregory A Grabowski & Thomas A Burrow
Drug Evaluation: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
The benefits of including expansion cohorts in Phase I oncology clinical trial design
Aaron R Hansen, Albiruni RA Razak
Editorial: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Essential thrombocythemia: new advances in an old disease
Clodagh Keohane , Claire Harrison
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Clinical evidence for the role of eribulin mesylate in the treatment of breast cancer
Carole Gourmelon, Jean Sebastien Frenel,Mario Campone
Review: Clinical Trail Outcomes: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation
-
Antibiotic treatment of acute otitis media in children: to wait or not to wait?
Eugene Leibovitz
Editorial: Clinical Investigation